After Joint Replacement Surgery, Smokers at Increased Risk of Reoperation for Infection
15-Feb-2017 4:30 PM EST
Newswise — February 15, 2017 – For patients undergoing total hip or knee replacement, smoking is associated with an increased risk of infectious (septic) complications requiring repeat surgery, reports a study in the February 15 issue of The Journal of Bone & Joint Surgery. The journal is published by Wolters Kluwer.
"Our results found that current smokers had a significantly higher rate of septic reoperation compared with nonsmokers," commented senior author Dr. Matthew S. Austin of the Rothman Institute at Thomas Jefferson University, Philadelphia. "Furthermore, each additional pack-year significantly contributed to total reoperations."
Smokers Show 80 Percent Increase in Risk of Reoperations for Infection The researchers looked at how smoking history affected the risk of hospital readmissions among patients undergoing total joint replacement—either hip or knee replacement. The study included data on 15,264 patients who underwent a total of 17,394 total joint replacements between 2000 and 2014—8,917 hip and 8,477 knee replacements.
At the time of surgery, nine percent of patients were current smokers, 34 percent were former smokers, and 57 percent were nonsmokers. Current smokers were younger than nonsmokers: average age was about 58 versus 63 years. Smokers also had higher rates of certain major respiratory and cardiovascular diseases.
The absolute risk of reoperation for infectious complications within 90 days was low: 0.71 percent. However, this risk was substantially higher for current smokers: 1.2 percent, compared to 0.56 percent for nonsmokers.
After adjustment for other characteristics, current smokers remained at significantly increased risk of reoperation for infectious complications—the relative risk was 80 percent higher, compared to nonsmokers. As a group, former smokers were not at increased risk.
However, for current and former smokers alike, the risk of 90-day nonoperative readmission increased with the number of "pack-years" smoked. Smoking an extra pack per day for a decade was associated with a 12 percent increase in that relative risk. Smoking overall, however, was unrelated to the risk of readmission without surgery, or for reoperation for reasons other than infections.
Total joint replacement (also called arthroplasty) is an effective treatment for advanced degenerative joint disease. Nearly one million total joint replacements—most commonly of the hip and knee— were performed in the United States in 2011. The demand for these procedures is expected to increase over the next decade.
Although some important risk factors for complications have been identified, the relationship between smoking and complications after total hip or knee replacement has been unclear. Minimizing unplanned hospital readmissions is a major focus of efforts to improve the quality and value of healthcare.
While there's no difference in the total readmission rate, the new results suggest that current smokers are at substantially higher risk of reoperation for septic complications. Patients with a history of heavier smoking are also at increased risk, even if they have since quit smoking.
"If smoking is associated with elevated perioperative risk of readmission and/or reoperation, then it may be reasonable to engage the patient in a smoking cessation program prior to total joint arthroplasty," Dr. Austin and coauthors write. However, further studies would be needed to determine whether quitting smoking before joint replacement surgery can reduce the risk of complications.
Article: “Smoking Increases the Rate of Reoperation for Infection within 90 Days After Primary Total Joint Arthroplasty” (doi: 10.2106/JBJS.16.00311)
About The Journal of Bone & Joint SurgeryThe Journal of Bone & Joint Surgery (JBJS) has been the most valued source of information for orthopaedic surgeons and researchers for over 125 years and is the gold standard in peer-reviewed scientific information in the field. A core journal and essential reading for general as well as specialist orthopaedic surgeons worldwide, The Journal publishes evidence-based research to enhance the quality of care for orthopaedic patients. Standards of excellence and high quality are maintained in everything we do, from the science of the content published to the customer service we provide. JBJS is an independent, non-profit journal.
About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer's market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.
Wolters Kluwer reported 2015 annual revenues of €4.2 billion. The group serves customers in over 180 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY). Wolters Kluwer Health is a leading global provider of information and point of care solutions for the healthcare industry. For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.